2012-10-05 17:05:40 - New Pharmaceuticals market report from Global Markets Direct: "Cholera - Pipeline Review, H2 2012"

Global Markets Direct's, 'Cholera - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cholera, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cholera. Cholera - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/468484_cholera_pipeline_review_h2_2012.aspx


Scope

* A snapshot of the global therapeutic scenario for Cholera.
* A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Cholera pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Cholera.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cholera Overview
Therapeutics Development
An Overview of Pipeline Products for Cholera
Cholera Therapeutics under Development by Companies
Cholera Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Cholera Therapeutics - Products under Development by Companies
Cholera Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Cholera Therapeutics Development
Napo Pharmaceuticals, Inc.
Vaccine Technologies, Inc.
PaxVax
Cholera - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
crofelemer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peru-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bivalent Killed Oral Cholera Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cholera Toxin B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dukoral Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PXVX-0200 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cholera Therapeutics - Drug Profile Updates
Cholera Therapeutics - Dormant Products
Cholera - Product Development Milestones
Featured News & Press Releases
Mar 19, 2012: FDA Accepts PaxVax's IND For Single-Dose Oral Cholera Vaccine
Aug 26, 2008: Crucell to move Dukoral and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004
Feb 25, 2003: Dukoral Approved In Canada
Mar 11, 2002: European Marketing Authorisation Application Submitted For Dukoral
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Cholera, H2 2012
Products under Development for Cholera - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Napo Pharmaceuticals, Inc., H2 2012
Vaccine Technologies, Inc., H2 2012
PaxVax, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468484&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.